ORPHA:618
Familial melanoma
Publications
1,514
Trials
1
Interventional, condition-specific
Researchers
1,423
Distinct authors in sample
Gene link
—
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
Familial melanoma (FM) is a rare inherited form of melanoma characterized by development of histologically confirmed melanoma in two first degree relatives or more relatives in an affected family.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0018961
- UMLS:C1512419
- NCIT:C8498
Additional Mondo synonyms (1)
hereditary melanoma (disease)
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
1,514 matched papers (641 in last 10 years) Source
- Phenotype characterisedPresent
12 HPO annotations (e.g. Retinopathy; Freckling; Abnormality of extrapyramidal motor function) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
1 matched on ClinicalTrials.gov (1 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
12
Associated phenotypes · MONDO:0018961
- Retinopathy
- Freckling
- Abnormality of extrapyramidal motor function
- Neoplasm of the pancreas
- Nevus
Showing 5 of 12 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
1,514
1,514 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
1,514 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
641 in the last 10 years · low confidence
Phrase hits: 1,514 · MeSH hits: 0
Who's working on it?
1,423
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Puig S14 papers · 2023
Melanoma Unit, Dermatology Department, Hospital Clinic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.
Papers in Europe PMC - 02Soyer HP13 papers · 2025
Dermatology Research Centre, The University of Queensland Diamantina Institute, Brisbane, Australia.
Papers in Europe PMC - 03van Doorn R11 papers · 2026
Department of Dermatology, LUMC, Leiden, The Netherlands.
Papers in Europe PMC - 04Hayward NK10 papers · 2026
QIMR Berghofer Medical Research Institute, Herston, Australia.
Papers in Europe PMC - 05McInerney-Leo AM10 papers · 2024
Translational Genomics Group, Institute of Health and Biomedical Innovation, Queensland University of Technology (QUT) at Translational Research Institute, Woolloongabba, Queensland, Australia.
Papers in Europe PMC - 06Adams DJ9 papers · 2026
Experimental Cancer Genetics Group, Wellcome Trust Sanger Institute, Hinxton, Cambridge, U.K.
Papers in Europe PMC - 07Goldstein AM9 papers · 2026
Human Genetics Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
Papers in Europe PMC - 08Potrony M9 papers · 2023
Melanoma Unit, Dermatology Department, Hospital Clinic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.
Papers in Europe PMC - 09Höiom V8 papers · 2025
Department of Oncology Pathology, Karolinska Institutet and Karolinska University Hospital Solna, Stockholm, Sweden.
Papers in Europe PMC - 10Tucker MA8 papers · 2026
Human Genetics Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
1
interventional trials for this specific condition
1 interventional trial matched this specific condition name; 1 currently recruiting in our sample. 2,889 trials are registered for melanoma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026
1 interventional trial — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 80.1th percentile).
low confidence · 80.1th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
1 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT06767332·RECRUITING·EMDR for Fear of Cancer Recurrence in Patients with Familial Melanoma: a Waiting List Control Trial
Not reviewed·Conditions: Familial Melanoma · Fear of Cancer Recurrence · Eye Movement Desensitization and Reprocessing · Psychological Intervention·Matched via name phrase
Broader category: melanoma
2,889
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07114172·NOT YET RECRUITING·Study of Melanoma-Resistant PET Monitoring Based on Key Rate-limiting Enzymes for Fatty Acid Metabolism in Healthy Volunteers
Not reviewed·Conditions: Melanoma (Skin Cancer) · Health Volunteers · PET / CT·Matched via name phrase
- NCT07070518·RECRUITING·Study of GV20-0251 in Participants With Solid Tumor Malignancies
Not reviewed·Conditions: Solid Tumor Cancer · Adult Refractory Cancer · Endometrial Carcinoma (EC) · Squamous Head and Neck Carcinoma·Matched via name phrase
- NCT05968690·RECRUITING·Naltrexone and Propranolol Combined With Immunotherapy
Not reviewed·Conditions: Advanced Melanoma·Matched via name phrase
- NCT06545682·RECRUITING·Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)
Not reviewed·Conditions: Melanoma (Skin Cancer) · Breast Cancer · Brain Metastasases·Matched via name phrase
- NCT05955924·RECRUITING·Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients - Pivotal Trial
Not reviewed·Conditions: Non-melanoma Skin Cancer · Carcinoma, Squamous Cell · Carcinoma, Basal Cell · Keratinocyte Carcinoma·Matched via name phrase
- NCT07459543·NOT YET RECRUITING·A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India
Not reviewed·Conditions: Untreated Melanoma · Unresectable Melanoma · Metastatic Melanoma·Matched via name phrase
- NCT06066138·RECRUITING·A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
Not reviewed·Conditions: Locally Advanced Alveolar Soft Part Sarcoma · Metastatic Alveolar Soft Part Sarcoma · Locally Advanced Non Small Cell Lung Cancer · Metastatic Non Small Cell Lung Cancer·Matched via name phrase
- NCT04119024·RECRUITING·Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Not reviewed·Conditions: Metastatic Malignant Solid Neoplasm · Metastatic Melanoma · Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 · Pathologic Stage IV Cutaneous Melanoma AJCC v8·Matched via name phrase
- NCT06739226·RECRUITING·Combination Immunotherapy Targeting Melanoma
Not reviewed·Conditions: Melanoma·Matched via name phrase
- NCT06214156·RECRUITING·A Clinical Study of T3011 in Subjects With Advanced Melanoma
Not reviewed·Conditions: Advanced Melanoma·Matched via name phrase
- NCT04282044·RECRUITING·Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
Not reviewed·Conditions: Solid Tumor, Adult · Triple Negative Breast Cancer · Colorectal Cancer · Hepatocellular Carcinoma·Matched via name phrase
- NCT07581509·NOT YET RECRUITING·Pharmacokinetics, Safety, and Immunogenicity of Bmab1800 and Keytruda® as Adjuvant Monotherapy in Patients With Melanoma
Not reviewed·Conditions: Adult Patients With Stage IIB, IIC, and Stage III Melanoma Following Complete Resection (Adjuvant Settings)·Matched via name phrase
- NCT05704647·RECRUITING·Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases
Not reviewed·Conditions: Melanoma (Skin)·Matched via name phrase
- NCT07371663·RECRUITING·An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
Not reviewed·Conditions: Solid Cancers · NSCLC (Advanced Non-small Cell Lung Cancer) · Gastric (Stomach) Cancer · Endometrial Cancer·Matched via name phrase
- NCT06708663·RECRUITING·HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours
Not reviewed·Conditions: Biliary Tract Cancer · Melanoma·Matched via name phrase
Observational and natural-history studies
1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
None of the matched observational studies is currently listed as recruiting.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 27 · after dedupe 26 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 26 · dropped 0 · fetched 2026-07-29
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (26)
- isrctn·ISRCTN15681288·Recruiting·Restoring intestinal symbiosis for efficacy in IBS
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN65517362·No longer recruiting·Treating IBS with an Intestinal Microbiota Product for Health - TrIuMPH
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN62546421·Recruiting·The European registry of familial pancreatic cancer and hereditary pancreatitis
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16463547·Recruiting·CRISTAL-APC - a trial of chemokine receptor inhibition for patients with pancreatic cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN13695430·No longer recruiting·A feasibility trial to assess recruitment rates and ctDNA reporting times for patients with resected stage IIB/IIC/IIIA melanoma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16103145·No longer recruiting·Injection of IP-001 into thermally ablated solid tumors
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11460478·Recruiting·A clinical trial adding Sativex (a cannabis-based medicine) to standard treatment, temozolomide, to find out if it is beneficial for patients whose glioblastoma brain tumour has returned after treatment
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN30808508·No longer recruiting·A comparison of response to treatment in patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN) Overlap Syndromes taking ASTX727 versus best supportive care
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN94991276·Stopped·DETECTION Trial: Using blood tests to guide early treatment of relapse in early stage melanoma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN46841867·No longer recruiting·A phase II and phase III trial comparing treatment escalation and de-escalation strategies in newly diagnosed patients with multiple myeloma suitable for stem cell transplant
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN47127434·Recruiting·A trial to look for markers in the tumour cells and blood which signal that trial treatments are working in a patient with triple negative breast cancer, for whom upfront chemotherapy has not provided the maximum expected benefit: PHOENIX
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16431108·No longer recruiting·Family History Lifestyle Study
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14634058·Stopped·PARIS-Pembrolizumab in combination with radiotherapy in locally advanced non-small cell lung cancer (NSCLC)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN35236442·Stopped·Neoadjuvant intraviTreal ranibizumab treatment in high-risk ocular melanoma patients
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN01207094·No longer recruiting·Autologous stem cell transplantation for patients with amyloid light chain (AL) amyloidosis
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN36205515·No longer recruiting·Zoledronate on bone mineral density in patients with cancer remission and anti-neoplastic treatment induced bone loss
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN18543567·No longer recruiting·MINDACT (Microarray In Node-negative Disease may Avoid Chemotherapy): a prospective, randomised study comparing the 70-gene signature with the common clinical-pathological criteria in selecting patients for adjuvant chemotherapy in node-negative breast cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN49320109·Recruiting·A CAR T trial for amyloid light chain amyloidosis (AL Amyloid)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14643179·Recruiting·Assessing if stopping and starting standard of care medication for later stage melanoma can reduce the body's resistance to the treatment
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14048364·Recruiting·Testing and comparing multiple drugs at once against the standard treatment for progressive multiple sclerosis treatment
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11043249·No longer recruiting·A study to assess the relationship between disease flare states and participant-reported health data, health data from a wearable activity tracker, and biomarker data in participants with inflammatory bowel disease (IBD)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14595136·No longer recruiting·A study of encorafenib and binimetinib given before and after surgery, compared with standard treatment after surgery, in patients with BRAF-mutant melanoma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16867955·Recruiting·A randomised phase 3 trial evaluating the role of finasteride in increasing compliance with active surveillance, in men with a new diagnosis of low and intermediate risk prostate cancer, when compared with usual care.
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11885863·No longer recruiting·Investigating the safety and efficacy of a Universal CAR-T cell immunotherapy in patients with relapse and refractory B-cell acute lymphoblastic leukemia and B lymphoblastic lymphoma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15073006·No longer recruiting·Lowering Events in Non-proliferative retinopathy in Scotland
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Familial melanoma — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Familial melanoma" OR "hereditary melanoma (disease)"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Familial melanoma" OR "hereditary melanoma (disease)"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 1 interventional · 1 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"melanoma"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (1514) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-26T14:35:24.288Z
